Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis
Gabriel Barsotti(Yale University), Madhav C. Menon(Yale University), Elizabeth Peck(Icahn School of Medicine at Mount Sinai), E. M. Tanvir(Yale University), Prashant Patel(Yale New Haven Hospital), Jia Fu(Harbin Medical University), Lloyd G. Cantley(Yale University), Joji Tokita(Icahn School of Medicine at Mount Sinai), Randy L. Luciano(Yale University), Dennis G. Moledina(Yale University), Sudhir Perincheri, Kristin Meliambro(Icahn School of Medicine at Mount Sinai), Abhijit S. Naik(University of Michigan), Anand Reghuvaran(Yale University), John Pell(Yale University), Ashwani Kumar(Yale University), Vijayakumar R. Kakade(Yale University), F. Perry Wilson(Yale University), Weijia Zhang(Shandong University), Li Fan(Nanjing Medical University), Gilbert Moeckel(Yale University), John Cijiang He(James J. Peters VA Medical Center)
Cited by 3
Related Papers
SARS–CoV-2 infection of the placenta
|Journal of Clinical Investigation|2020|492
Glomerular endothelial cell injury and cross talk in diabetic kidney disease
|American Journal of Physiology-Renal Physiology|2014|274
Reversed-engineered human alveolar lung-on-a-chip model
|Proceedings of the National Academy of Sciences|2021|246
Single-Cell RNA Profiling of Glomerular Cells Shows Dynamic Changes in Experimental Diabetic Kidney Disease
|Journal of the American Society of Nephrology|2019|215
Rationale and design of the Kidney Precision Medicine Project
|Kidney International|2021|187